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We have become aware of several instances of precipitous
and, in our view, egregious and unjustified closures of on-
going clinical trials in which a substantial number of
patients were already participating in investigational
efforts, some involving biopsies for research purposes.
These closures raise serious ethical issues for the research
community. We will discuss those issues and some possi-
ble changes in how trials are conducted to address the
problem. It is our premise that closing on-going clinical
trials without scientific, efficacy, or safety justification is an
abhorrent affront to all participants in clinical research as
well as a fundamental betrayal of the trust that motivates
patient participants to enroll in clinical trials.
Cancer patients who accept the risk of an investigational
drug are true partners in bringing new agents to market.
They hope they will benefit but, regardless of personal
benefit/response, they hope the researchers will learn
something to help other patients. Patients participate in
clinical research for multiple reasons but, particularly in
the case of agreeing to undergo mandatory research biop-
sies, do so because the research has the potential to
improve the care, treatment approach, and standards for
cancer patients. They engage in a relationship with
researchers based on their trust in the integrity of the
researchers and the system within which the researchers
work. Any cavalier approach to the commitment patients
make to research is indefensible and particularly repre-
hensible when participants undergo internal organ biopsies.
Violating the trust of these patients also violates the trust
the patients place in the investigators, undermining patient
confidence in and availability for research. That trust and
any violation of it are deepened when the researcher is also
a given patient’s treating oncologist.
It is with good reason that human beings who enroll in
clinical trials are called participants, not subjects. A par-
ticipant is one who takes part in something—an active,
volitional partner or colleague. A subject is one, mouse or
human, who is under the power or authority and at the
incontestable will of another or others. That difference
between a participant and a subject is significant and ger-
mane to this discussion of when and why it is or is not
appropriate to close a clinical trial. Human participants
have a choice about joining a trial and that choice is
heavily influenced by the participants’ perceptions of the
integrity, ethics, and trustworthiness of the investigators
and sponsors.
The travesty of sponsors unilaterally closing on-going
clinical trials for business reasons not related to the sci-
ence, efficacy, or safety of the trial may be the shared
secret of the cancer research community. Some are silent
because they are perpetrators. Some are silent because they
are fearful of loss or retribution for speaking. Most tragi-
cally, some, patient participants, are victims unaware.
Whatever the reasons, the lack of active outrage is deeply
troubling. We, the advocates and researchers, must ask
ourselves are we looking the other way when we should be
standing up for patients and challenging the process? Is our
silence simply acceptance, or worse, apathy? Consider
Martin Niemoeller’s reported observation on his own
silence: ‘‘…they came for ….[others] so I did not speak
out. And when they came for me, there was no one left to
speak out for me.’’
Unilateral trial closing absent safety concerns, unplan-
ned analyses of the outcome of the study, or changes in the
risk/benefits threatens the foundation of clinical research
and betrays trust. Precipitous and inappropriate closure of
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an on-going clinical trial has far-reaching implications that
raise significant issues about the ethics of clinical trials and
the trust that patients exhibit by participating in the clinical
research process. Some of the potential implications
include the participants being treated as lab rats, rein-
forcing an old, negative stereotype of clinical trials;
reduction of enrollment in future trials; and diminishment
of the reputation of both the researchers and the research
sites as well as the sponsors. These are issues that need to
be seriously considered.
Any early termination decision, especially in trials
where patients agree to biopsies for research purposes only,
must have scientific, efficacy, or safety justification. Clo-
sure for any other reason, such as realigning financial
investments or changing priorities, is a blatant violation of
the trust patients place when signing a consent form. Early
trial closures not related to the conduct of the trial nega-
tively affect the science that can be learned from the
biopsies collected due to the much smaller sample size.
The ability to make conclusions on the correlative studies
becomes underpowered, substantially compromising the
risk–benefit of performing these procedures.
Well-conducted, focused research has the best potential
for advancing the treatment and possible cure of cancer
patients; therefore, it is imperative that scientific decisions
be based on scientific criteria. Those scientific decisions
must be the basis of trial continuation or closure. There-
fore, we recommend that Phase II studies of a certain size
or complexity have an independent Data and Safety
Monitoring Board.
Closing clinical studies for non-scientific, non-safety, or
non-efficacy reasons is not only unacceptable and uncon-
scionable but also violates the moral and ethical standards
of beneficent research with human participants. The
appropriate action is to complete the study as specified in
the protocol. It is in the best interest of the patients and the
science to do so. The larger issue is that measures must be
in place to prevent actions of this kind in the future, as
failure to do so will undermine translational research with
human participants, an essential link in the drive to reduce
and, someday, remove the burden of cancer.
Those of us who are involved in the conduct of cancer
research, advocates, researchers, and sponsors, must be
aware that research involving human participants is a
contract with participants, not a use of subjects. Therefore,
we must ask ourselves this question: If failure to fully
honor the research contract with cancer patients does not
bother us, what will?
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